As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals

Nicole DeFeudis

Editor

BioNTech’s Covid-19 vaccine took center stage at the company’s Q1 call with investors on Monday — and though execs saw sales triple last quarter, they’re also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

As BioN­Tech pre­dicts a drop in its moth­er lode of Covid sales, ex­ecs hint at com­ing M&A deals

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals